openPR Logo
Press release

Flu Detection Device Market : Industry Survey and Outlook 2024

06-23-2017 04:18 PM CET | Health & Medicine

Press release from: Transparency Market Research

Flu Detection Device Market : Industry Survey and Outlook 2024

Influenza, commonly known as flu, is a contagious respiratory ailment caused in humans by influenza virus A and influenza virus B. There are three types of influenza viruses, namely, A, B and C; of these, type A virus is the most virulent strain. Type A strains can infect humans as well as animals, while influenza type B viruses exclusively infect human. Type C viruses are less common and cause mild diseases in children. Influenza viruses are RNA viruses and have two large glycoproteins, namely hemagglutinin (HA) and neuraminidase (NA), which are targets for antibody detection devices. Flu usually spreads during seasonal epidemics, which brings about deaths of thousands of people every year and millions during pandemic outbreaks. According to a World Health Organization report, seasonal epidemics worldwide are responsible for 3-5 million cases of severe illness, leading to 250,000 to 500,000 deaths every year. Currently used Influenza detection devices are either class I devices or class II devices. Flu detection devices detect antigens using specific labeled antibody or they work on nucleic acid amplification principle. In the 20th century, three influenza pandemics were reported, each of these pandemic being brought on by new strains of viruses in humans. There are fifteen subtypes of influenza viruses, of which H1N1, H2N2, H3N2, H5N1, H7N7 and H1N2 strains outbreaks were reported by WHO. In April 2009, a new influenza strain called Influenza A/H1N1 or swine flu emerged that consolidated genes from human, pig and bird avian virus. The flu emerged in the U.S., Mexico, and several other nations.

Obtain Report Details @ http://www.transparencymarketresearch.com/flu-detection-device-market.html

Influenza is a contagious ailment and is easily communicable and thus, requires rapid and accurate diagnosis for infection control and patient management. Influenza is treated using three types of products namely, prevention products, treatment products and diagnostics products. Increasing prevalence of chronic diseases, rising government initiatives and growing consumer awareness about pandemic and seasonal epidemics are some of the driving factors of flu detector device market. Rising geriatric population and advancements in influenza diagnostics tests are factors supporting growth of the flu detector device market. However, high development cost of flu detection device is projected to restrain growth of flu detector device market in the near future.

The global flu detection device market is segmented on the basis of product type, disease indication, end users and region. On the basis of product type, the global flu detection device market can be further segmented into Rapid Influenza Detection Test (RIDT), Direct Fluorescence Antibody Tests (DSFA), Direct Fluorescence Antibody Test (DFA) and Point of Care Detection device. These flu detection device products fall under FDA’s Class I devices and Class II devices. Flu detection devices provide diagnosis on the basis of various techniques such as reverse transcription-PCR, ELISA, antibody binding, and electrospray ionization- mass spectrometry. On the basis of disease indication, flu detection device market is categorized into Influenza A, Influenza A/B and RSV virus detection. On the basis of end users, the market is segmented into hospitals, specialized clinics, diagnostic centers, research laboratories and contract research organizations.

Worldwide outbreak of seasonal and pandemic influenza ailments and emergence of novel influenza viruses is increasing risk to public health due to which, the rapid influenza detection test segment is expected to account for the largest share of the global flu detection device market. However, the FDA pointed out the poor performance of RIPD test during 2009 pandemic outbreak which is projected to restrain growth of this segment in flu detection device market to a certain extent. As per CDC estimations, around 60.8 million cases of H1N1 influenza were reported in the U.S. in 2009. Thus, on the basis of disease indication, Influenza A segment is expected to expand at a high CAGR over the forecast period.

The global flu detection device market is divided into five key regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. In terms of geography, North America is expected to account for major market share in the global flu detection device market. Asia and Europe also account for considerable market share in the flu detection device market and are expected to witness significant growth in the near future. Rapid growth of the market in these regions is attributed to increasing prevalence of chronic diseases and rising geriatric population.

Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16448

Some of the key players in this market are Cepheid (U.S.), Roche Molecular Systems Inc. (U.S.), Becton, Dickinson and Company (U.S.), Alere (U.S.), Meridian Life Sciences (U.S.), Thermo Fisher Scientific Inc., Fast-track diagnostics Ltd., R-Biopharm AG, Sekisui Diagnostics, DiaSorin Molecular LLC., Maccura, and LifeSign PBM.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Flu Detection Device Market : Industry Survey and Outlook 2024 here

News-ID: 594630 • Views: 259

More Releases from Transparency Market Research

Impact of Outbreak of COVID-19 on Medical Education Market : Global Industry Ana …
Transparency Market Research (TMR) has published a new report on the medical education market for the period of 2019–2027. According to the report, the global medical education market was valued at nearly US$ 31 Bn in 2018, and is projected to expand at a CAGR of more than 4% from 2019 to 2027. Rise in the number of medical schools and increase in cost of medical education are the
Healthcare BI Platform Market Companies Analysis, Advancement and Precise Outloo …
In an intensely competitive healthcare business intelligence (BI) platform market, large players are aggressively focused on expanding their geographical outreach, says Transparency Market Research (TMR) in a new market intelligence report. These large players are leveraging the cloud business model to provide healthcare BI solutions that can be accessed irrespective of location. Apart from this, savvy players are entering into partnerships with hospital groups and healthcare bodies to integrate healthcare BI
Substance Abuse Treatment Market News Research Report 2024
A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their
Clinical Oncology Next Generation Sequencing Market is Thriving Worldwide By Siz …
Clinical Oncology Next Generation Sequencing: Introduction Next generation sequencing for tumor and germline DNA is required for oncology screening for therapeutic application. Rise in burden of cancer increases the need for early detection of the condition to carry out the generate target therapy. Companies are investing to develop technologically advanced devices/solutions for precision detection. In 2012, Oxford Nanopore had launched the GridION sequencing platform, which can sequence a human genome in 15

All 5 Releases


More Releases for Influenza

Influenza Diagnostics Market – Screening Product Awareness 2025
Global Influenza Diagnostics Market: Snapshot The global market for influenza diagnostics is slated to expand at a promising pace in the next few years as the incidences of influence are rising at a massive pace on the globe front. A common illness of the respiratory system, the condition is responsible for between 250,000 to 500,000 deaths across the globe every year. As the virulent spread of the condition creates increased concerns
Influenza B Infection Market Endeavors Growth 2025
Global Influenza B Infection Market: Snapshot Influenza B infection is considered as one of the common conditions that affects a large number of people across the globe, caused due to the influenza virus B genera of the family. The condition of influenza B infection requires proper medications and treatments in order to avoid severe complications. At present, several medicines and vaccinations are made available in order to reduce the incidence of
Influenza Diagnostics Market
Influenza, commonly known as flu, is an infectious disease caused by the influenza virus. Three varieties of this virus affect people: type A, type B, and type C. Influenza spreads through infectious respiratory secretions caused by aerosol formation due to direct contact with an infected person. This virus can cause seasonal epidemics with high levels of morbidity and mortality. According to WHO, these epidemics were estimated to result in about
Uprising European Influenza Vaccine Market- Ken Research
Europe is at the heart of global vaccine research and production. Influenza is a vaccine preventable disease and influenza vaccine has been available for use in Europe since 1960’s. Approximately, at US$ 1 billion, Europe influenza market was closed. Nevertheless, the highest influenza market share was held by United Kingdom. West Europe has more than US$ 500 Million. United Kingdom, Germany, France, Italy and Spain hold 80 percent of influenza market
Global Influenza Vaccine Market Forecast
Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine
Influenza Diagnostics Market Analysis – 2024
Influenza, commonly known as flu, is an infectious disease caused by the influenza virus. Three varieties of this virus affect people: type A, type B, and type C. Influenza spreads through infectious respiratory secretions caused by aerosol formation due to direct contact with an infected person. This virus can cause seasonal epidemics with high levels of morbidity and mortality. According to WHO, these epidemics were estimated to result in about